Vitality Watch

Dossier pubmed review 15-sep-2026
Narrative review or expert overview without new data

Cuproptosis in age-related orthopedic diseases: mechanisms and therapeutic prospects.

Key claim: Cuproptosis—copper-dependent mitochondrial regulated cell death via lipoylated TCA-protein aggregation and Fe–S cluster loss—may contribute to age-related orthopedic diseases (OA, OP, IVDD) and is a candidate therapeutic target.

Abstract

Cuproptosis is an emerging copper-dependent and mitochondria-associated form of regulated cell death (RCD) that links intracellular labile copper accumulation to metabolic vulnerability. Mechanistically, cuproptosis is triggered by intracellular copper accumulation, leading to aggregation of lipoylated tricarboxylic acid (TCA) cycle proteins, destabilization of iron-sulfur cluster proteins, and proteotoxic stress-induced bioenergetic collapse. Aging-associated orthopedic disorders-including osteoarthritis (OA), osteoporosis (OP) and intervertebral disc degeneration (IVDD)-represent a rapidly expanding global burden and share convergent pathological features such as mitochondrial dysfunction, oxidative stress, chronic low-grade inflammation, and progressive skeletal cell loss. However, the upstream regulatory networks integrating these hallmarks remain incompletely defined. Aging may be accompanied by systemic copper redistribution, impaired intracellular copper buffering, expansion of labile copper pools in vulnerable cellular microenvironments, and concomitant iron dysregulation. Together, these alterations form an interconnected metal-redox-metabolic axis that sensitizes skeletal tissues to degenerative remodeling. In this review, we synthesize current advances in copper homeostasis and the molecular determinants of cuproptosis, with particular emphasis on their potential involvement in OA, OP, and IVDD. We further distinguish established evidence from mechanistic hypotheses and discuss why serum copper, tissue copper, and intracellular labile copper should not be interpreted interchangeably. Finally, we outline future perspectives on targeting cuproptosis for the treatment of age-related orthopedic diseases, aiming to stimulate further clinical investigation and therapeutic innovation.

Why this matters

Cuproptosis is a young cell-death pathway with a specific mitochondrial signature (lipoylated TCA-protein aggregation, Fe–S cluster loss) that maps onto the same biology already implicated in aging: bioenergetic collapse, mtDNA/DAMP leakage, and sterile inflammation. Extending it to osteoarthritis, osteoporosis, and IVDD gives the field a candidate unifying mechanism for age-related orthopedic tissue loss and a rationale for copper-chelation approaches — but the entire proposal is currently hypothesis-generating, with no human evidence that copper overload is a rate-limiting driver of these diseases or that lowering it changes joint, bone, or disc outcomes.

Source

Link

Briefing card

Cuproptosis in age-related orthopedic diseases: mechanisms and therapeutic prospects.
Stage: review · pubmed · 15-sep-2026

If you are tracking copper-chelation or 'cuproptosis-targeting' pitches for arthritis, osteoporosis, or disc disease, this is currently a review-level mechanistic hypothesis with no human trial evidence behind it.

Cuproptosis—copper-dependent mitochondrial regulated cell death via lipoylated TCA-protein aggregation and Fe–S cluster loss—may contribute to age-related orthopedic diseases (OA, OP, IVDD) and is a candidate therapeutic target.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.intimp.2026.117419

build build 880 · 2bcef25 · 2026-11-18